tetano
Editor, Senior Moderator
Pediatr Infect Dis J. 2017 Jul 14. doi: 10.1097/INF.0000000000001693. [Epub ahead of print]
[h=1]A Retrospective Cohort Study of the Incidence, Healthcare Resource Utilization, and Costs of ICD-9 Diagnosed Influenza and Related Complications in US Children.[/h] Buck PO[SUP]1[/SUP], Smith DM, Shenolikar R, Irwin DE.
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] There is a paucity of data on the clinical and economic impact of seasonal influenza in children. This study estimated the incidence of diagnosed influenza and related complications, and associated healthcare resource utilization (HRU) and costs in US children.
[h=4]METHODS:[/h] Children ≥6 months and <18 years old diagnosed with influenza using ICD-9 codes and enrolled in a health plan during at least one influenza season between 2010-2014 were matched to similar patients without diagnosed influenza (GSK study identifier: HO-15-15728). Outcomes included incidence of influenza and complications, HRU frequency, and healthcare costs during 21 days of follow-up. Adjusted costs were estimated using generalized linear models.
[h=4]RESULTS:[/h] Incidence (per 1,000) of influenza was 20.3 (commercially-insured) and 32.6 (Medicaid), with the highest incidence among 6 to 35-month olds (Commercial: 26.8; Medicaid: 47.9). Approximately 12-17% of influenza patients experienced complications, with the 6-35 months group having the highest percentage (25-30%). The 6-35-month-old influenza patients with complications had the highest proportion with hospitalizations (5-6%) and emergency room visits (Commercial: 19%; Medicaid: 36%). Influenza patients with (vs. without) complications had greater adjusted mean influenza-specific costs (Commercial: $1,161 vs. $337; Medicaid: $1,199 vs. $354; p<0.05), and influenza cases (vs. controls) had greater adjusted mean all-cause costs (Commercial: $688 vs. $470; Medicaid: $818 vs. $453; p<0.05).
[h=4]CONCLUSIONS:[/h] Pediatric patients with influenza incurred higher healthcare costs compared with matched controls, and influenza-specific costs were greater among those with complications.
PMID: 28719499 DOI: 10.1097/INF.0000000000001693
[h=1]A Retrospective Cohort Study of the Incidence, Healthcare Resource Utilization, and Costs of ICD-9 Diagnosed Influenza and Related Complications in US Children.[/h] Buck PO[SUP]1[/SUP], Smith DM, Shenolikar R, Irwin DE.
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] There is a paucity of data on the clinical and economic impact of seasonal influenza in children. This study estimated the incidence of diagnosed influenza and related complications, and associated healthcare resource utilization (HRU) and costs in US children.
[h=4]METHODS:[/h] Children ≥6 months and <18 years old diagnosed with influenza using ICD-9 codes and enrolled in a health plan during at least one influenza season between 2010-2014 were matched to similar patients without diagnosed influenza (GSK study identifier: HO-15-15728). Outcomes included incidence of influenza and complications, HRU frequency, and healthcare costs during 21 days of follow-up. Adjusted costs were estimated using generalized linear models.
[h=4]RESULTS:[/h] Incidence (per 1,000) of influenza was 20.3 (commercially-insured) and 32.6 (Medicaid), with the highest incidence among 6 to 35-month olds (Commercial: 26.8; Medicaid: 47.9). Approximately 12-17% of influenza patients experienced complications, with the 6-35 months group having the highest percentage (25-30%). The 6-35-month-old influenza patients with complications had the highest proportion with hospitalizations (5-6%) and emergency room visits (Commercial: 19%; Medicaid: 36%). Influenza patients with (vs. without) complications had greater adjusted mean influenza-specific costs (Commercial: $1,161 vs. $337; Medicaid: $1,199 vs. $354; p<0.05), and influenza cases (vs. controls) had greater adjusted mean all-cause costs (Commercial: $688 vs. $470; Medicaid: $818 vs. $453; p<0.05).
[h=4]CONCLUSIONS:[/h] Pediatric patients with influenza incurred higher healthcare costs compared with matched controls, and influenza-specific costs were greater among those with complications.
PMID: 28719499 DOI: 10.1097/INF.0000000000001693